GlassScriptPhysician profile
Philip Nmi Gibbs
NPI 1548283617
$3,471.43
in general payments reported to CMS, 2019-2025
26 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $438 · 2021: $1,085 · 2022: $455 · 2023: $344 · 2024: $269 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $904 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.56 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $745.27 | 2019-2023 | Farxiga, Andexxa |
| Janssen Pharmaceuticals, INC | $462.92 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $382.00 | 2019-2025 | |
| Pfizer INC. | $250.16 | 2019-2025 | |
| Amgen INC. | $246.92 | 2019-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.08 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.66 | 2021-2025 | |
| Abbvie INC. | $138.95 | 2021-2023 | |
| Cmp Pharma, INC. | $97.08 | 2021-2022 | |
| Kyowa Kirin, INC. | $96.26 | 2021-2023 | Crysvita |
| Kowa Pharmaceuticals America, INC. | $92.72 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $90.18 | 2024-2025 | Voquezna |
| Mylan Specialty L.P. | $70.88 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $61.11 | 2021-2023 | Verquvo, Belsomra |
| Esperion Therapeutics, INC. | $59.47 | 2024-2025 | Nexletol |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.17 | 2024-2025 | Xifaxan |
| Kiniksa Pharmaceuticals, LTD. | $47.88 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $45.36 | 2019-2023 | Camzyos |
| Amarin Pharma, INC. | $45.08 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $35.81 | 2020-2021 | |
| Inspire Medical Systems, INC. | $34.96 | 2024 | Inspire |
| Ultragenyx Pharmaceutical INC. | $26.86 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.70 | 2022 | |
| Alnylam Pharmaceuticals INC. | $22.21 | 2024 | Oxlumo |
| Takeda Pharmaceuticals U.S.A., INC. | $20.50 | 2019 | |
| Scpharmaceuticals INC. | $14.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Gibbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.